BioSpace News Archive

Medison Pharma today announced the addition of new markets to its multi-territorial agreement with Immunocore Holdings plc.

Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals and vaccines, today announced that Dr. Shankar Musunuri, Chairman, CEO and Co-Founder of Ocugen, will participate in an in-person fireside chat at the H.C. Wainwright Global Investment Conference, on May 24, 2022, at 1:30pm ET in Miami Beach, Florida.

Shockwave Medical, Inc. and Genesis MedTech Group announced today that they have successfully obtained approval from China’s National Medical Products Administration (NMPA) to market and sell the Shockwave IVL System with the Shockwave C 2 Coronary IVL Catheters and the Shockwave M 5 and S 4 Peripheral IVL Catheters in China.

Fennec Pharmaceuticals Inc., a specialty pharmaceutical company focused on the development of PEDMARKTM for the prevention of platinum-induced ototoxicity in pediatric patients, announced that the Company will be participating in upcoming conferences.

Stealth BioTherapeutics Corp announced new data from the ReCLAIM-2 study of elamipretide in geographic atrophy (GA) secondary to dry age-related macular degeneration (dry AMD) at the Clinical Trials at the Summit meeting in Lake Tahoe, Nevada.

Soligenix, Inc. announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the patent application titled “Compositions and Methods of Manufacturing Trivalent Filovirus Vaccines.”

Kala Pharmaceuticals, Inc. announced that it has entered into a definitive agreement to sell its commercial portfolio and related intellectual property assets to Alcon Inc.

Plandai Biotechnology Inc. announced its entry into a non-binding letter of intent to enter into a new business through a proposed product and technology rights licensing agreement with the holder of rights to the unique Puriblood Leukocyte Reduction Blood Filtration System.

Albany NY, United States: Allergy is a harmful immune response by the body to substances such as pollens, specific food, and dust, which are responsible for hypersensitivity.

The corporate intelligence reports predict that the global human microbiome market will record an astounding compound annual growth rate of 31.1 % over the forecast years i.e. 2023 to 2029.